An analysis of more than 1,400 NHS‑referred long COVID patients suggests that ENO Breathe delivers measurable improvements in quality of life, mental health and respiratory symptoms including breathlessness.
This provides another robust clinical evidence for the programme’s impact on long-term respiratory and mental wellbeing, following the Randomised Controlled Trial undertaken by Imperial College in 2022.
The newly published study analysed outcomes from 1,438 participants referred through 51 NHS long COVID services across England, making it one of the largest real‑world evaluations of a creative health intervention for long COVID breathlessness to date. Participants who completed the six‑week programme experienced clinically meaningful improvements across multiple validated health measures, with 61% achieving clinically important improvements in breathlessness. Engagement levels were high, and no serious adverse events were reported.
These findings build on earlier evidence from a Randomised Controlled Trial (RCT) published in The Lancet Respiratory Medicine in April 2022, further strengthening the clinical evidence base for ENO Breathe and its potential for integration at scale within NHS services.
The study is published in The Lancet Digital Health, the world’s most prominent publishing venue in digital health, and can be read in full here: www.thelancet.com/journals/landig/article/PIIS2589-7500(26)00011-7/fulltext
Suzi Zumpe, Creative Director of ENO Breathe, said: “Creativity is key to our approach: participants don’t just learn techniques, they discover what works for them. By using imagery and imagination, we help people get out of their own way, unlocking a new perspective and restoring a sense of agency. Singing lullabies builds emotional connections with the wider set of ideas and practices that make up ENO Breathe. Participants finish sessions with a calming song in their hearts and a positive connection to tools, making them more memorable, more meaningful and more usable.”